102 related articles for article (PubMed ID: 24986687)
1. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.
Aubrey BJ; Kelly GL; Kueh AJ; Brennan MS; O'Connor L; Milla L; Wilcox S; Tai L; Strasser A; Herold MJ
Cell Rep; 2015 Mar; 10(8):1422-32. PubMed ID: 25732831
[TBL] [Abstract][Full Text] [Related]
2. Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals.
Tai X; Erman B; Alag A; Mu J; Kimura M; Katz G; Guinter T; McCaughtry T; Etzensperger R; Feigenbaum L; Singer DS; Singer A
Immunity; 2013 Jun; 38(6):1116-28. PubMed ID: 23746651
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.
Manier S; Huynh D; Shen YJ; Zhou J; Yusufzai T; Salem KZ; Ebright RY; Shi J; Park J; Glavey SV; Devine WG; Liu CJ; Leleu X; Quesnel B; Roche-Lestienne C; Snyder JK; Brown LE; Gray N; Bradner J; Whitesell L; Porco JA; Ghobrial IM
Sci Transl Med; 2017 May; 9(389):. PubMed ID: 28490664
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic cell death in disease-Current understanding of the NCCD 2023.
Vitale I; Pietrocola F; Guilbaud E; Aaronson SA; Abrams JM; Adam D; Agostini M; Agostinis P; Alnemri ES; Altucci L; Amelio I; Andrews DW; Aqeilan RI; Arama E; Baehrecke EH; Balachandran S; Bano D; Barlev NA; Bartek J; Bazan NG; Becker C; Bernassola F; Bertrand MJM; Bianchi ME; Blagosklonny MV; Blander JM; Blandino G; Blomgren K; Borner C; Bortner CD; Bove P; Boya P; Brenner C; Broz P; Brunner T; Damgaard RB; Calin GA; Campanella M; Candi E; Carbone M; Carmona-Gutierrez D; Cecconi F; Chan FK; Chen GQ; Chen Q; Chen YH; Cheng EH; Chipuk JE; Cidlowski JA; Ciechanover A; Ciliberto G; Conrad M; Cubillos-Ruiz JR; Czabotar PE; D'Angiolella V; Daugaard M; Dawson TM; Dawson VL; De Maria R; De Strooper B; Debatin KM; Deberardinis RJ; Degterev A; Del Sal G; Deshmukh M; Di Virgilio F; Diederich M; Dixon SJ; Dynlacht BD; El-Deiry WS; Elrod JW; Engeland K; Fimia GM; Galassi C; Ganini C; Garcia-Saez AJ; Garg AD; Garrido C; Gavathiotis E; Gerlic M; Ghosh S; Green DR; Greene LA; Gronemeyer H; Häcker G; Hajnóczky G; Hardwick JM; Haupt Y; He S; Heery DM; Hengartner MO; Hetz C; Hildeman DA; Ichijo H; Inoue S; Jäättelä M; Janic A; Joseph B; Jost PJ; Kanneganti TD; Karin M; Kashkar H; Kaufmann T; Kelly GL; Kepp O; Kimchi A; Kitsis RN; Klionsky DJ; Kluck R; Krysko DV; Kulms D; Kumar S; Lavandero S; Lavrik IN; Lemasters JJ; Liccardi G; Linkermann A; Lipton SA; Lockshin RA; López-Otín C; Luedde T; MacFarlane M; Madeo F; Malorni W; Manic G; Mantovani R; Marchi S; Marine JC; Martin SJ; Martinou JC; Mastroberardino PG; Medema JP; Mehlen P; Meier P; Melino G; Melino S; Miao EA; Moll UM; Muñoz-Pinedo C; Murphy DJ; Niklison-Chirou MV; Novelli F; Núñez G; Oberst A; Ofengeim D; Opferman JT; Oren M; Pagano M; Panaretakis T; Pasparakis M; Penninger JM; Pentimalli F; Pereira DM; Pervaiz S; Peter ME; Pinton P; Porta G; Prehn JHM; Puthalakath H; Rabinovich GA; Rajalingam K; Ravichandran KS; Rehm M; Ricci JE; Rizzuto R; Robinson N; Rodrigues CMP; Rotblat B; Rothlin CV; Rubinsztein DC; Rudel T; Rufini A; Ryan KM; Sarosiek KA; Sawa A; Sayan E; Schroder K; Scorrano L; Sesti F; Shao F; Shi Y; Sica GS; Silke J; Simon HU; Sistigu A; Stephanou A; Stockwell BR; Strapazzon F; Strasser A; Sun L; Sun E; Sun Q; Szabadkai G; Tait SWG; Tang D; Tavernarakis N; Troy CM; Turk B; Urbano N; Vandenabeele P; Vanden Berghe T; Vander Heiden MG; Vanderluit JL; Verkhratsky A; Villunger A; von Karstedt S; Voss AK; Vousden KH; Vucic D; Vuri D; Wagner EF; Walczak H; Wallach D; Wang R; Wang Y; Weber A; Wood W; Yamazaki T; Yang HT; Zakeri Z; Zawacka-Pankau JE; Zhang L; Zhang H; Zhivotovsky B; Zhou W; Piacentini M; Kroemer G; Galluzzi L
Cell Death Differ; 2023 May; 30(5):1097-1154. PubMed ID: 37100955
[TBL] [Abstract][Full Text] [Related]
5. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
Pisano M; Cheng Y; Sun F; Dhakal B; D'Souza A; Chhabra S; Knight JM; Rao S; Zhan F; Hari P; Janz S
Front Immunol; 2021; 12():667054. PubMed ID: 34149703
[TBL] [Abstract][Full Text] [Related]
6. Mouse models of multiple myeloma: technologic platforms and perspectives.
Rossi M; Botta C; Arbitrio M; Grembiale RD; Tagliaferri P; Tassone P
Oncotarget; 2018 Apr; 9(28):20119-20133. PubMed ID: 29732008
[TBL] [Abstract][Full Text] [Related]
7. Viewing BCL2 and cell death control from an evolutionary perspective.
Strasser A; Vaux DL
Cell Death Differ; 2018 Jan; 25(1):13-20. PubMed ID: 29099481
[TBL] [Abstract][Full Text] [Related]
8. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.
Brinkmann K; Grabow S; Hyland CD; Teh CE; Alexander WS; Herold MJ; Strasser A
Cell Death Differ; 2017 Dec; 24(12):2032-2043. PubMed ID: 28800129
[TBL] [Abstract][Full Text] [Related]
9. PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.
Guirguis AA; Slape CI; Failla LM; Saw J; Tremblay CS; Powell DR; Rossello F; Wei A; Strasser A; Curtis DJ
Cell Death Differ; 2016 Jun; 23(6):1049-59. PubMed ID: 26742432
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Bim in Health and Disease.
Sionov RV; Vlahopoulos SA; Granot Z
Oncotarget; 2015 Sep; 6(27):23058-134. PubMed ID: 26405162
[TBL] [Abstract][Full Text] [Related]
11. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression.
Mérino D; Strasser A; Bouillet P
Oncogene; 2012 Jul; 31(28):3392-6. PubMed ID: 22081075
[TBL] [Abstract][Full Text] [Related]
12. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
[TBL] [Abstract][Full Text] [Related]
13. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex.
Gomez-Bougie P; Oliver L; Le Gouill S; Bataille R; Amiot M
Oncogene; 2005 Dec; 24(54):8076-9. PubMed ID: 16091744
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.
Vandenberg CJ; Waring P; Strasser A; Cory S
Blood; 2014 Aug; 124(7):1099-109. PubMed ID: 24986687
[TBL] [Abstract][Full Text] [Related]
15. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.
Grabow S; Delbridge AR; Aubrey BJ; Vandenberg CJ; Strasser A
Cell Rep; 2016 Mar; 14(10):2337-47. PubMed ID: 26947081
[TBL] [Abstract][Full Text] [Related]
16. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
